期刊文献+

复方奥硝唑甲磺酸培氟沙星缓释牙栓毒理学实验研究 被引量:1

Toxicological experiment study of Compound Ornidazole and Pefloxacinmesylat Sustained-release Periodontal Suppository
下载PDF
导出
摘要 目的了解动物对复方奥硝唑甲磺酸培氟沙星缓释牙栓的毒理学反应,为开发应用牙周病治疗新药提供试验依据。方法按新药的有关要求进行如下试验:(1)昆明小鼠最大耐受量(MTD)试验;(2)SD大鼠慢性毒理学试验;(3)豚鼠皮肤过敏试验;(4)SD大鼠牙周黏膜毒性及刺激试验;(5)新西兰兔眼部刺激试验。结果动物MTD为8.4g/kg;该药物对动物的肝功、肾功、血常规及5个重要脏器均无明显影响;对皮肤和牙周黏膜无刺激;该药眼刺激实验平均得分≤3分,在用药48h后全部消失,为可逆变化,属无刺激。结论动物对该药物有很大的耐受性,毒性低,可以进一步深入临床研究。 Objective To assure the animals' response to the toxicology of Compound Ornidazole and Pefloxacinmesylat Sustained-release Periodontal Suppository, and to provide experimental basis for development and application of the new drug for the therapy of periodontosis. Methods The following tests were done according to the requirements of developing new drugs. (1)The maximal tolerance dose(MTD) test on K unming rats. (2)The chronic toxicology test on standard rats. (3)The skin allergic test on guinea pigs. (4)The oral mucosa toxic and irritating tests on SD rats. (5)The eyes irritating tests on rabbits. Results MTD was 8.4g/kg body weight. It had no evident impact on routine blood test, liver function test, kidney function test and 5 important organs of the animal, and it also had no irritating and allergic effect on skins and oral mucosa. The average grade in the eyes was≤3, but it rapidly disappeared in 48h. which meant that there were no irritating effects. Conclusion Animals have good tolerance to the new drug with low toxicity, which is safe for clinical research.
出处 《重庆医学》 CAS CSCD 2007年第2期130-132,共3页 Chongqing medicine
基金 重庆市科委基金资助项目(2004BB5065)
关键词 奥硝唑 甲磺酸培氟沙星 牙栓 缓释 毒理学 ornidazole pefloxacinmesylate periodontal suppository sustained-release toxicology
  • 相关文献

参考文献8

  • 1段延华,刘鲁川,蒋艳,李楠,张莉,熊辉,孟德胜.奥硝唑和培氟沙星不同配伍对牙周病原菌体外抗菌作用[J].口腔医学研究,2006,22(2):162-165. 被引量:8
  • 2蒋艳,刘鲁川,李楠,段延华.奥硝唑牙栓的制备及质量控制[J].第三军医大学学报,2006,28(9):990-991. 被引量:12
  • 3Shayne C.Gad.Drug Safty Evaluation[M].北京:化学工业出版社,2006.106
  • 4Abraham MH,Kumarsingh R,Cometto-Muniz JE,et al.Draize eye scores and eye irritation thresholds in man canbe combined into one QSAR[J].Ann NY Acad Sci,1998,6:652
  • 5Citron DM,Tyrrell KL.In vitro activity of oritavancin (LY333328),vanc-omycin,clindamycin and metronidazole against Clostridium perfringens,Propionibacte-rium acnes,and anaerobic Gram-positive cocci[J].Anaerobe,2005,11(2):93
  • 6Kamma JJ,Nakou M,Mitsis FJ.The clinical and microbiological effects of systemic ornidazole in sites with and without subgingival debridement inearly-onset periodontitis patients[J].J Periodontol,2000,71(12):1862
  • 7Wu P,Lawrence LE,Denbleyker KL,et al.Mechanism of action of the Des-F(6) quinolone BMS-284756 measured by supercoiling inbibition and cleavable complex assays[J].J Antimicorb Agents Chemother,2001,45(14):3660
  • 8Marc Quirynen,Wim Teughels.Topic antiseptics and antibiotics in the initial theraphy of chronic adult periodontitis:microbiological aspects[J].Periodontology,2002,28(2):72

二级参考文献14

  • 1刘学聪,边百川,张玉.奥硝唑糊剂治疗牙周炎的近期疗效观察[J].现代中西医结合杂志,2004,13(15):2019-2019. 被引量:12
  • 2李从荣,金正江,詹,丁俊清,李艳,彭少华.奥硝唑治疗口腔厌氧菌感染的临床与实验研究[J].中华医院感染学杂志,2004,14(3):325-327. 被引量:40
  • 3Cennet Celik.In vitro activities of tinidazole and metronidazole against clostridium diffieile,prevotellabivia and bacteroides fragilis[J].Anaerobe,2005,4(17):101-103
  • 4周学东,肖晓蓉.口腔微生物学[M].四川大学出版社,2001,4(15):390-407
  • 5Socransky S,Haffajee A.Evidence of aetiology:a historical perspective[J].Periodontol,2000,1994(5):7-10
  • 6Zambon JJ.Periodontal diseases:microbial factors[J].An Periodontol,1996,1(12):879-883
  • 7Tyrrell KL.In vitro activity of oritavancin (LY333328),vancomycin,clindamycin,and metronidazole against Clostridium perfringens,Propionibacterium acnes,and anaerobic Gram-positive cocci[J].Anaerobe,2005,11(2):93-95
  • 8Kamma JJ,Nakou M,Mitsis FJ.The clinical and microbiological effects of systemic ornidazole in sites with and without subgingival debridement in early-onset periodontitis patients[J].Periodonto,2000,71(12):1 862-1 865
  • 9Sydney M.Antimicrobial susceptibilities of Bacteroides fragilis and Bacteroides thetaiotaomicron strains isolated from clinical specimens and human intestinal microbiota[J].Anaerobe,2004,10(5):255-259
  • 10TROMBELLI L,TATAKIS D N.Periodontal diseases:current and future indications for local antimicrobial therapy[J].Oral Dis,2003,9 (Suppl 1):11 -15.

共引文献16

同被引文献7

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部